DDInter927 DDInter822
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile.
Glasdegib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Glasdegib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Glasdegib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Glasdegib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levosalbutamol
Glasdegib {u} may lead to a major life threatening interaction when taken with {v} Bedaquiline
Glasdegib {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Glasdegib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Glasdegib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Glasdegib may lead to a major life threatening interaction when taken with Bedaquiline
Glasdegib may lead to a major life threatening interaction when taken with Ivosidenib